Cell and gene therapies (CGTs) have advanced from conceptual promise to clinical reality, with dozens of approved products and thousands more in development. A unifying feature across this pipeline is the viral vector: an engineered virus optimized to deliver therapeutic payloads with high efficiency. 

This post distills what we believe are the most important of those decisions, drawing on the panel discussion, our own experience working across cell therapy, gene therapy, and complex biologics programs, and the patterns we see repeated in programs that land successfully in the clinic and beyond.